RxDoctor Payments Data

Micah Wright, DO

Obstetrics & Gynecology · Tulsa, OKNPI 1295195824

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,130 of the $7,104 with a category attached, or 86.3%. 16 manufacturers reported payments, led by Axonics, Inc. at 25.5% of the total. Reporting peaked in 2023 at $2,027 and has fallen 64.2% since, to $725 in 2025.

$7,104in general payments, 2019–2025

Across 128 payments — averaging $55.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Minerva Surgical, Inc$2K
  • Intuitive Surgical$781
  • AbbVie$721
  • Gynesonics, Inc.$631
  • Astellas Pharma US Inc$340
  • plus $1K from 10 others

What the payments were for

  • Travel & lodging$89613%
  • Food & beverage$6,13086%
  • Education$551%
  • Gifts$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,104 in reported general payments places this provider in the 85th percentile of 396 obstetrics & gynecology providers in Oklahoma.

See all obstetrics & gynecology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$28,539
Medicare patients
71
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron345$151,820
PremarinEstrogens, Conjugated103$37,186
Estradiol24$712
Oxybutynin Chloride47$651
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$364
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$340$151,820345 claims
PfizerPremarin$86$37,186103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 396 obstetrics & gynecology providers in Oklahoma.

Other obstetrics & gynecology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →